Ignite Creation Date:
2025-12-24 @ 11:37 PM
Ignite Modification Date:
2025-12-25 @ 9:27 PM
Study NCT ID:
NCT05101356
Status:
RECRUITING
Last Update Posted:
2024-05-21
First Post:
2021-10-19
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
Sponsor:
Tianhong Li
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-10-13
Start Date Type:
ACTUAL
Primary Completion Date:
2026-01-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-01-01
Completion Date Type:
ESTIMATED
First Submit Date:
2021-10-19
First Submit QC Date:
None
Study First Post Date:
2021-11-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-19
Last Update Post Date:
2024-05-21
Last Update Post Date Type:
ACTUAL